Market Cap 5.40M
Revenue (ttm) 0.00
Net Income (ttm) -13.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 80,100
Avg Vol 196,884
Day's Range N/A - N/A
Shares Out 7.44M
Stochastic %K 18%
Beta 0.25
Analysts Strong Buy
Price Target $2.00

Company Profile

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, inclu...

Industry: Biotechnology
Sector: Healthcare
Phone: 786 977 3380
Address:
1111 Lincoln Road, Suite 500, Miami Beach, United States
Jeasie
Jeasie Jul. 31 at 4:38 PM
$KTTA Pas - 004 showing target engagement in phase 1 Watch for rerate
0 · Reply
Jeasie
Jeasie Jul. 31 at 12:57 PM
0 · Reply
Pharma_Stock_Calls
Pharma_Stock_Calls Jul. 31 at 11:54 AM
$KTTA yet another target hit with huge gains. We sent alert 3 days ago. Follow for more.
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 31 at 11:08 AM
$KTTA Pharmacodynamic data indicates up to 91% pERK inhibition, reflecting robust target engagement. Preliminary activity included stable disease and modest tumor reductions in solid tumor patients
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 31 at 11:06 AM
$KTTA pt $1+
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 31 at 11:06 AM
$KTTA Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients By Pasithea | July 31, 2025, 7:01 AM
0 · Reply
Pharma_Stock_Calls
Pharma_Stock_Calls Jul. 28 at 2:45 PM
$SPY $KTTA ✅ 💊 $KTTA Entry: $0.7265 → Target: $0.81
0 · Reply
BioTechHealthX
BioTechHealthX Jul. 20 at 5:07 PM
$KTTA Backed by institutional money and a best-in-class drug candidate, Pasithea may be poised for liftoff. Explore the bullish case now. https://biotechhealthx.com/biotech-news/pasithea-therapeutics-ktta-just-raised-5-million-is-this-the-spark-it-needed/
0 · Reply
JustinDTLV
JustinDTLV Jul. 14 at 11:21 PM
$KTTA Nice AH volume compared to the past few trading days.
0 · Reply
encostock
encostock Jul. 12 at 10:01 AM
0 · Reply
Latest News on KTTA
Why Is Pasithea Therapeutics Stock Surging On Thursday?

Sep 26, 2024, 8:56 AM EDT - 11 months ago

Why Is Pasithea Therapeutics Stock Surging On Thursday?


Jeasie
Jeasie Jul. 31 at 4:38 PM
$KTTA Pas - 004 showing target engagement in phase 1 Watch for rerate
0 · Reply
Jeasie
Jeasie Jul. 31 at 12:57 PM
0 · Reply
Pharma_Stock_Calls
Pharma_Stock_Calls Jul. 31 at 11:54 AM
$KTTA yet another target hit with huge gains. We sent alert 3 days ago. Follow for more.
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 31 at 11:08 AM
$KTTA Pharmacodynamic data indicates up to 91% pERK inhibition, reflecting robust target engagement. Preliminary activity included stable disease and modest tumor reductions in solid tumor patients
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 31 at 11:06 AM
$KTTA pt $1+
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 31 at 11:06 AM
$KTTA Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients By Pasithea | July 31, 2025, 7:01 AM
0 · Reply
Pharma_Stock_Calls
Pharma_Stock_Calls Jul. 28 at 2:45 PM
$SPY $KTTA ✅ 💊 $KTTA Entry: $0.7265 → Target: $0.81
0 · Reply
BioTechHealthX
BioTechHealthX Jul. 20 at 5:07 PM
$KTTA Backed by institutional money and a best-in-class drug candidate, Pasithea may be poised for liftoff. Explore the bullish case now. https://biotechhealthx.com/biotech-news/pasithea-therapeutics-ktta-just-raised-5-million-is-this-the-spark-it-needed/
0 · Reply
JustinDTLV
JustinDTLV Jul. 14 at 11:21 PM
$KTTA Nice AH volume compared to the past few trading days.
0 · Reply
encostock
encostock Jul. 12 at 10:01 AM
0 · Reply
StockFlips
StockFlips Jul. 11 at 12:56 PM
$KTTA starter in
2 · Reply
KhalidsCapital
KhalidsCapital Jul. 7 at 5:36 AM
$ONFO $KTTA Keep these on the radar
0 · Reply
JustinDTLV
JustinDTLV Jul. 4 at 2:48 AM
$KTTA received a notice from Nasdaq for not meeting the $1.00 minimum bid price requirement. They have until December 22 (180 days) to regain compliance. https://www.sec.gov/Archives/edgar/data/1841330/000121390025059004/ea0246913-8k_pasithea.htm
0 · Reply
Adubstradesmini
Adubstradesmini Jul. 3 at 10:56 PM
0 · Reply
Fib7867
Fib7867 Jul. 2 at 10:03 PM
#myKTTAanalysis $KTTA
0 · Reply
user5588
user5588 Jul. 2 at 8:19 PM
$KTTA there’s been very little movement but if you look at the daily candles there have been so many green days.
0 · Reply
Kidpicasso
Kidpicasso Jun. 30 at 12:19 PM
0 · Reply
PoPPoP26
PoPPoP26 Jun. 27 at 2:13 PM
$KTTA guess only way to get the chat room going is come out w news. otherwise we been in this accumulation period.
2 · Reply
PoPPoP26
PoPPoP26 Jun. 24 at 9:50 PM
$KTTA has been holding strong just accumulate the shares. 1000 here 1000 there over the last 3 weeks and staying in this range. Its going to boogey soon.
0 · Reply
Kidpicasso
Kidpicasso Jun. 24 at 7:48 PM
$KTTA In. Looks ripe.
1 · Reply
Doeyex
Doeyex Jun. 24 at 6:42 PM
0 · Reply
PoPPoP26
PoPPoP26 Jun. 24 at 3:25 PM
$KTTA time for the monster to wake up. Been hanging like this for the last 3 weeks.
0 · Reply